Clinical Research Directory

Inclusion Criteria: * Has degenerative disc disease and is indicated for lumbar interbody spine fusion from L2-S1 with INFUSE™ Bone Graft via ALIF or OLIF technique * Agrees to participate in the study and is able to understand and sign the Informed Consent * The procedure planned for the patient complies with the labeling of the devices that may be used in the surgical procedure * Has at least six months of nonoperative treatment prior to the study treatment * Is at least 18 years old at the time of informed consent Exclusion Criteria: * Has a known hypersensitivity to recombinant human Bone Morphogenetic Protein-2, bovine Type I collagen, or to other components of the formulation * Has any active malignancy or undergoes treatment for a malignancy, or operative site is in the vicinity of a resected or extant tumor * Is skeletally immature (\<18 years of age or no radiographic evidence of epiphyseal closure) * Is pregnant or lactating * Has an active infection at the operative site or with an allergy to titanium, titanium alloy, or polyetheretherketone * The use of the Infuse™ Bone Graft component implanted at locations other than the lower lumbar spine (e.g., cervical spine) * Repeat applications of the Infuse™ Bone Graft component * Has up to Grade 1 retrolisthesis * Has hepatic or renal impairment * Has metabolic bone disease * Has autoimmune disease * Has immunosuppressive disease or suppressed immune systems resulting from radiation therapy, chemotherapy, steroid therapy, or other treatments * Is illiterate or vulnerable (e.g., the participant is incapable of judgment or is under tutelage) as per the investigator's assessment * Concurrent participation in another clinical study that may confound study results * Has a considerable risk for surgery * Has a condition that could compromise study (e.g., mentally incompetent, alcohol or drug abuse) as per the investigator's assessment